Pharmacokinetic and Pharmacodynamic Equivalence of Biocon’s Proposed Biosimilar Insulin-R to Humulin-R

January 17, 2022

Insulin costs have increased dramatically in recent years, and the study authors note that high costs for many patients result in nonadherence or insulin rationing, leading to diabetic complications and even death.

Wayne Winegarden, PhD Discusses Which Insurance Type He Expects Will Have the Greatest Biosimilar Savings
International Biosimilars Trade Group Appoints New Leadership for 2022
The Top 5 Biosimilar Articles for the Week of January 10
Michigan Trade Group Outlines Best Practices for Biosimilar Adoption